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Recent advances have increased excitement about the potential for therapeutic production of red blood
cells (RBCs) in vitro. However, generation of RBCs in the large numbers required for transfusion remains
a significant challenge. In this article, we summarize recent progress in producing RBCs from various cell
sources, and discuss the hurdles that remain for translation into the clinical arena.Unmet Transfusion Needs
Blood transfusion is an indispensable cell therapy. The safety
and adequacy of the blood supply are national and international
priorities. With over 93 million donations made every year
worldwide, the blood supply in industrialized countries is
adequate overall. The number of units collected exceeded
those transfused by 13% in the USA in 2008. There are,
however, several shortcomings to the current system.
Due to the substantial polymorphism of blood group antigens,
there are, even in developed countries, chronic shortages of
blood for some patient groups (Zimring et al., 2011). Immune
reactivity problems are magnified when donors and recipients
are from different ethnic groups. In the USA, more than 40% of
Sickle Cell Anemia patients, who are largely of African descent,
experience immune reactions when transfused with blood from
donors, who are mostly of Caucasian descent. Targeted recruit-
ment programs have aimed to balance the ethnicity of donors
and recipients but disparities in supply and demand still exist
for rare blood units. Data from Life-Share Blood Centers
(http://www.lifeshare.org/facts/raretraits.htm; Shreveport, LA)
indicate that screening of 17,603 donors identified only 101
donors with the rare U negative phenotype to serve a population
of 30 chronically transfused U negative patients.
Sporadic shortages of blood can also occur in association
with natural or man-made disasters. In emergencies, national
plans call for sponsoring emergency blood drives, but the infra-
structure to maintain blood collection and distribution systems
may be disrupted during disasters of severe magnitude, such
as the recent earthquake in Japan. For this reason, emergency
plans also call for sharing of blood resources across geograph-
ical areas and accessing frozen blood inventories, which are
limited.
There is also increasing concern that the blood supply may
be curtailed by new restrictions on donor eligibility as new
blood transmissible diseases are discovered and/or emerging
diseases, such Dengue fever, spread to new geographical
areas, increasing unit rejection due to positivity for transmissible
disease. In addition, blood usage by the growing numbers of
individuals >60 years of age is predicted to increase, leading to
an insufficient blood supply by 2050.Over the years, the transfusion medicine community has
evaluated several alternative transfusion products (TPs),
including hemoglobin solutions, perfluorocarbons, and enzy-
matically/chemically modified RBCs to produce ORh-negative
blood. Only hemoglobin solutions moved to phase 3 clinical
trials. A meta-analysis of 16 clinical trials demonstrated that
use of hemoglobin solutions leads to increased risk for myocar-
dial infarction and death (Natanson et al., 2008). Against this
backdrop, research on in vitro expanded RBCs as alternative
TPs has gained new momentum (Figure 1).
The Search for the Optimal Stem Cell Source
Theconcept of using in-vitro-generatedRBCsasaTParosewhen
it was realized that currently discarded primary stem cell sources
(low volume cord blood [CB] and cells discarded during the leu-
koreduction process of adult blood [AB] donations) have the
potential to generate sufficient RBCs for several transfusions (Mi-
gliaccioet al., 2009;Peyrardet al., 2011).However,due to intrinsic
differences in hematopoietic stemcell (HSC) content and in prolif-
eration ability of hematopoietic progenitor cells, the number of
RBCs generated from sources from different individuals varies
over two-logs (Migliaccio et al., 2009). Understanding the factors
underlying this variability will optimize donor selection, an impor-
tant facet of in vitro production of TPs from primary sources.
Current technologies are able to produce sufficient RBCs for
their functional evaluation in vivo (107). In 2011, the Douay labo-
ratory provided evidence that autologous RBCs generated
in vitro under good manufacturing practice (GMP) conditions
from mobilized CD34pos cells collected by apheresis survive
in vivo in man as long as their natural counterparts do (deter-
mined by 51Cr labeling, the only method accepted by the US
Food and Drug Administration) when transfused into an autolo-
gous recipient (Giarratana et al., 2011). This study was received
with both excitement and reservations by the hematological
community. On one hand, it described the type of safety data
that could support an investigational new drug application. On
the other hand, however, its ultimate goal, therapeutic transfu-
sion, is still unrealistic based on the protocol described.
Although extensive, the potential of primary stem cells for
generating RBCs in vitro is limited. In principle, the ideal stemCell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 115
Figure 1. The Pathway to Therapeutic Production of Red Blood Cells from Stem Cells
Outline of the potential sources of stem cells for in vitro therapeutic products, including transfusion products (TPs) that are currently under investigation (top
panel), the different phases of a production process (middle panel), and a list of possible intermediate and long-term clinical applications of in-vitro-generated
erythroid cells (bottom panel). The diagram is color coded: intensity of red shades is inversely related to projected time for clinical application. Human hema-
topoietic stem/progenitor cells (HSC/HPC), immortalized erythroid precursor cells (EPC), and erythroblasts at different stages of maturation up to the RBC stage
in the expansion and maturation phase of the production process are represented. The culture protocols used to promote proliferation, maturation, and
enucleation of erythroid cells vary significantly. Therefore, the generation of TPs in vitro will require establishing sequential GMP conditions, the most challenging
of which may be represented by those that favor enucleation because of the need to replace the function exerted by stromal cells of murine origin with defined
components.
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expansion potential to justify the costs associated with its
characterization (viral screening; genomic, proteomic, and
epigenomic profiling; etc.) for a production process that would
meet current GMP criteria for medicinal products (those of the
European Medicines Agency [http://www.ema.europa.eu] and
those of the US Food and Drug Administration [http://www.fda.
gov/BiologicsBloodVaccines]). Stem cell sources with unlimited
proliferation potential include human ESCs (hESCs) and induced
pluripotent stem cells (iPSCs) (Yamanaka and Blau, 2010). The
potential genomic instability of these stem cells poses a reduced
safety concern in this context as the final cell product, RBCs,
does not contain a nucleus.
Seminal studies in 2006 from Dr. Nakamura and colleagues
established methods for generating RBCs from murine ESCs
(Miharada et al., 2006), and then in 2008 the same group demon-
strated that transfusion of ex-vivo-produced RBCs protects
mice from lethal hemolytic anemia (Hiroyama et al., 2008).116 Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc.Papayannopoulou and colleagues (Chang et al., 2006b) and
Lanza and colleagues (Lu et al., 2008) established methods for
generating RBCs from hESCs and provided extensive charac-
terization of the biological properties of these hESC-derived
RBCs. hESCs have been proposed as a source of stem cells
to generate universal ORh negative RBC TPs in vitro. However,
the genotype (O/ARh positive) of the three GMP-grade hESC
lines currently available (H1, H7, andH9) is not suitable for gener-
ating universal donor RBCs. Genotype characterization and
GMP-derivation of the additional 136 hESC lines currently avail-
able is needed to identify hESCs lines with the potential to
generate ORh negative RBCs. It would be evenmore challenging
to identify hESC lines suitable for generating RBCs for patients
with rare blood types. In theory, it might be possible to engineer
rare blood-specific hESC lines through homologous recombina-
tion (Zou et al., 2011). However, the genetic basis of some blood
group polymorphisms (as an example, Rh) is still not completely
understood (Zimring et al., 2011). Further studies on hESC
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would therefore be needed to generate blood-group specific
hESC lines.
As iPSCs can be generated from any donor, they are theoret-
ically suitable for generating phenotypically matched RBCs. It
has been calculated that iPSCs generated from donors with as
few as 24 rare blood phenotypes could produce TPs to accom-
modate virtually all patient groups in France (Peyrard et al.,
2011). However, identification of suitable donors is an intrinsic
limitation of this approach, because these phenotypes are
so rare that donors with the rarest of them may not exist. It
is more likely that iPSCs from dedicated rare donors would
be used to generate ex vivo TPs for their matched patients,
relieving pressure for continuous donations from the public.
A number of groups have published methods for generating
RBCs from iPSCs (Chang et al., 2011; Papapetrou et al.,
2011). In general, regardless of their origin, iPSCs generate
RBCs expressing mostly fetal hemoglobin (hemoglobin F).
RBCs expressing hemoglobin F are slightly less efficient than
those expressing adult hemoglobin for oxygen delivery. How-
ever, patients who retain expression of hemoglobin F in adult
life are not anemic. Thus, the fetal phenotype of RBCs derived
from iPSCs derived from patients with hemoglobinopathies is
not necessarily a barrier to their use as an autologous TP.
Additional barriers to the use of both hESCs and hiPSCs to
produce TPs include not only safety concerns (the phenotypic
instability of these cell lines poses some potential immunoge-
nicity risks for their products), but also current limitations on
large-scale hematopoietic cell expansion. HSCs derived from
hESCs and iPSCs have poor erythroid expansion potential
compared to that of CB (500 versus 104–105 erythroblasts per
hESC/iPSC-derived or CB-derived CD34pos cell, respectively).
Thus, production of TPs from hESCs and hiPSCs requires
enormous amplification of the hESCs and hiPSCs themselves.
However, the life span in culture of iPSCs is much longer than
that of HSCs from primary sources, making iPSCs better
suited to the selection procedures associated with genetic
manipulation (by genomic safe-harbor targeting [Papapetrou
et al., 2011] or homologous recombination [Zou et al., 2011]
technology) to generate in vitro, genetically corrected HSCs for
autologous transplantation in hematopoietic disorders.
Several investigators are exploring the feasibility of reprogram-
ming somatic cells directly into RBCs bypassing a pluripotent
state and/or generating stem cells with unlimited expansion
potential by epigenetic or genetic in vitro treatments. Treatment
with chromatin modifying agents increases the expansion poten-
tial of CB erythroid progenitor cells (Chaurasia et al., 2011).
Nakamura and colleagues have obtained immortal erythroid
precursor lines from murine ESCs (Hiroyama et al., 2011). In
both cases, the modified cells generated erythroblasts that
matured into circulating RBCs when injected into immunodefi-
cient NOD/SCID/gcnull mice. These in vivo analyses suggest
that in addition to being used to make TPs in vitro, these cells
might potentially be directly infused into patients in a manner
that is conceptually similar to the use of in-vitro-expanded
myeloid progenitor cells to reduce the period of neutropenia
following HSC transplantation. The generation of erythroid cells
by reprogramming somatic cells directly into erythroblasts by
overexpression of suitable gene combinations is also underinvestigation. A successful example of this approach is repre-
sented by the recent demonstration that overexpression of
p45NF-E2/Maf turns human fibroblasts into megakaryocytes
(Wang et al., 2011).
Economic and Logistical Challenges
Production of sufficient RBCs in vitro for transfusion (2.531012)
is currently a costly and technically challenging proposition.
One major technical limitation is the fact that erythroid cells do
not proliferate at a concentration >106 cells/ml, so production
of 231012 RBCs would require at least 2.53103 liters of culture
media. The only equipment currently available to manage such
large volumes is the bioreactors used by the biotechnology
industry. Whether bioengineering technology validated for
production of cell therapy products (e.g., the WAWE System or
perfusion hollow fibers) (Timmins et al., 2011; Housler et al.,
2011) will allow growth of erythroid cells at greater concentra-
tions, decreasing production costs, is currently unknown. A
better understandin of the mechanisms regulating the terminal
stages of erythroid differentiation and the identification of soluble
factors (hormones, inhibitors of cell adhesion and/or of the
death pathway, etc.) and/or cell-mediated factors, which may
increase the density limit atwhich erythroid cellsmaygrow, could
facilitate in vitro production of TPs by reducing the volume of
media required (Kim and Baek, 2011). An additional challenge
is that in vitro enucleation, the last step of erythroid maturation,
requires the presence of stromal cells, often of animal origin,
limiting the development of GMP production processes (Kim
and Baek, 2011). Methods to promote enucleation by using
chemical compounds that favor membrane trafficking (Keerthi-
vasan et al., 2010) also need to be developed. Overall, therefore,
considerable progress in areas such as formulation of humanized
culture media using clinical grade reagents, overcoming hurdles
to cell derivation, and development of bioengineering processes
and facilities to produce large numbers of cells will be required.
Intermediate Therapeutic Goals
In the interim, there are some realistic intermediate therapeutic
goals that could be achieved with current technology, in the
hope that, with adequate financial support, facilities for cost-
effective production of large numbers of RBCs will be available
by the time these intermediate benchmarks are reached. There
are at least three applications for in-vitro-generated RBCs that
are feasible with current technologies: reagent RBCs for anti-
body identification, drug discovery, and drug delivery. In-vitro-
generated cells are suited for these applications because their
immediate cell sources and precursors can be cryopreserved
and stored long-term for repeated study (Migliaccio et al., 2009).
Reagent RBCs
In vitro tests using RBCs from donors with common and rare
blood types are used to identify suitable transfusion matches
(Zimring et al., 2011). These antibody detection and identification
assays require low RBC numbers (23108 RBCs/100 assays),
but blood from rare donors is available in limited quantities
because guidelines restrict the frequency of donations to
prevent anemia. The need for additional donations could be
overcome by generating reagent RBCs in vitro from mononu-
clear cells usually discarded during the leukoreduction process
(or from iPSCs derived from these cells). Thorough comparisonCell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 117
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and in vivo would be important for validation of this application,
and such studies would also provide immunological/functional
information on their use as a TP.
Drug Discovery
Preclinical toxicology and efficacy drug evaluation guidelines
recommend reduction and eventually elimination of animal
experimentation through development of robust and sensitive
cell-based assays. Primary cells reflecting age, sex, and genetic
polymorphisms of the human population are more suitable than
cell lines for screening drugs that target diseases with variability
in clinical responses. Sensitive, fluorimetrically based miniatur-
ized assays have been developed that measure proliferation/
maturation rates of erythroblasts generated by several ml of
blood (Migliaccio et al., 2009). These assays have beenproposed
as an inexpensive way to screen for inducers of hemoglobin F
production for Thalassemia and Sickle Cell Anemia, inhibitors
of 11 kDa-mediated caspase 10 activation to prevent B19
parvovirus’ infection; cellular-based antimalarial therapies (e.g.,
lentiviral-induced miRNA overexpression to inhibit intracellular
proliferation of the parasite); and erythropoiesis-stimulating
agents for myelodysplatic syndrome. In addition, they could be
used for risk stratification in hematological malignancies and/or
optimization of therapy in cancer patients (Migliaccio et al., 2009).
Drug Delivery
Proof-of-principle for the use of erythroid cells for systemic drug
delivery has come from a mouse model of hemophilia. This
disease is an X-linked recessive congenital disorder of coagula-
tion due to Factor VIII or IX deficiency and is currently treated by
prophylactic factor infusion, which is expensive and requires
high patient compliance (biweekly administration). Transplanta-
tion with genetically engineered stem cells infected with a
retrovirus that enabled high-level Factor IX production by
RBCs (600–800 ng/ml human Factor IX/vector copy) cured
hemophilia B mice (Chang et al., 2006a). Although this type of
transplantation would not be considered for patients, it does
suggest that transfusion of RBCs expanded in vitro from genet-
ically modified autologous CD34pos cells might be a feasible
way to supply therapeutic levels of Factor IX. The normal serum
concentration of human Factor IX is 5,000 ng/ml but clinical
symptoms are substantially reduced with levels as low as
250 ng/ml. This level was obtained in the animal model with
30% genetically modified RBCs. Humans make 231011 retic-
ulocytes/day, so one can anticipate that a single transfusion of
30% of 231011 (i.e., 63109) Factor IX-producing RBCs would
be sufficient to maintain therapeutic levels of Factor IX for one
day and 4.231011 RBCs would be sufficient for at least
1 week. GMP facilities to produce 4.231011 RBCs already exist
and the cost to produce these cells may be affordable.
Safety Concerns
Before embarking on a phase 1 safety study, RBCs would
need to undergo further evaluation, including in vivo functional
studies in animal models (Giarratana et al., 2011). One caveat
of these analyses is that mice are poor models for human
erythropoiesis. However, a recent study showed that chemical
ablation of the macrophage pool greatly improves readouts of
human erythroid cells in NOD/SCID/gcnull mice (Hu et al.,
2011). In addition to establishing a reliable animal model for118 Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc.safety studies, this improved functional assay may finally enable
evaluation of whether erythroblasts could in fact represent an
innovative TP. Preliminary support for this idea comes from the
clinical observation that 40–80 ml of matched CB, which
contains 4–831010 RBCs plus 4–83107 erythroblasts, is some-
times used successfully for transfusions in developing countries
(Migliaccio et al., 2009). The major advantage of using erythro-
blasts as a TP is that each one could generate 4–64 RBCs in vivo,
reducing the cell numbers required for transfusion and the costs
and technical challenges of production. Erythroblast transfu-
sions would be also advantageous for some forms of chronic
anemia because, unlike transfused RBCs, erythroblasts may
reduce, rather than increase, iron overload. In addition, RBCs
generated in vivo by transfused erythroblasts would survive
longer in vivo, reducing the frequency of transfusion.
In-vitro-produced TPs must be subjected to the same safety
controls developed over time for donated blood. Donors should
be selected using the same rigorous procedures developed by
blood banks to minimize risks of infectious and immunological
diseases following transfusion (Zimring et al., 2011). Concerns
related to transmission of known and unknown adventitious
agents acquired duringmanufacturing could be addressed using
the same sterility tests developed by the pharmaceutical
industry and blood banks as part of their GMP procedures
(Giarratana et al., 2011). Concerns about transmission of
cells potentially transformed by extensive expansion stimuli or
other manipulations in culture could be reduced by terminal
filtration to eliminate nucleated cells, possibly in association
with irradiation, which also reduces the immunological risks of
graft versus host disease following transfusion (Zimring et al.,
2011). However, these techniques are not applicable to TPs con-
taining erythroblasts and/or immortalized erythroid precursors
(that are expected to be able to proliferate in vivo). Before being
considered for clinical use, these alternative TPs would need
to be evaluated thoroughly for risks associated with the accu-
mulation of genetic mutations. The long-term effects of adminis-
tration of in-vitro-expanded, autologous RBCs are unknown.
Even minor alterations in the expression of blood group antigens
and/or acquisition of neoantigens in culture would be of signifi-
cant concern because multiple administrations of large cell
numbers could lead to sensitization in both autologous and allo-
genic settings.
Concluding Remarks
In-vitro-generated erythroid cells including RBCs are needed to
address specific needs in transfusion medicine. In addition, they
may have broader uses as drug delivery vehicles and in other
specific circumstances. Although the generation of enucleated,
adult-like RBCs from hESCs and iPSCs still presents a number
of challenges, the goal of generating reagent red cells and TPs
is increasingly within reach.
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